deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT02656329

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device (ADMIRE-ICD)

AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 25%≤LVEF≤35%

Sponsor: ABX CRO

Conditions Heart Failure
Updated 19 times since 2017 Last updated: Apr 26, 2019 Started: Dec 30, 2015 Primary completion: May 4, 2018 Completion: May 4, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor discretion (low recruitment rate)

Other terminated trials from ABX CRO

More terminations from ABX CRO

This PHASE3 trial investigates Heart Failure and is currently terminated or withdrawn. ABX CRO leads this study, which shows 19 recorded versions since 2015 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

19 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

Show 14 earlier versions
  1. Aug 2019 — Jan 2021 [monthly]

    Terminated PHASE3

  2. Jun 2019 — Aug 2019 [monthly]

    Terminated PHASE3

    Status: SuspendedTerminated

  3. Jun 2018 — Jun 2019 [monthly]

    Suspended PHASE3

  4. Apr 2018 — Jun 2018 [monthly]

    Suspended PHASE3

    Status: RecruitingSuspended

  5. Feb 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  6. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  7. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  8. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  9. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  10. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  11. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  12. Mar 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  13. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ABX CRO
  • AG Mednet Inc.
  • Advanced Clinical, LLC
  • GE Healthcare
  • H2O Clinical LLC
  • ICON CEAC
  • ICON Clinical
  • TFS
  • TransPerfect
Data source: GE Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .